NCT07171606 A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients
| NCT ID | NCT07171606 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Shenyang Sunshine Pharmaceutical Co., LTD. |
| Condition | First-line Advanced NSCLC Patients |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2025-10-24 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 240 participants in total. It began in 2025-10-24 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study includes two parts, part 1 is SSGJ-706 monotherapy therapy for advanced NSCLC and part 2 is SSGJ-706 combination therapy for advanced NSCLC
Eligibility Criteria
Inclusion Criteria: 1. Males and/or females over age 18 2. Histologically and/or cytologically documented local advanced or metastatic NSCLC . 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Expected survival \>=3 months. 5. Signed informed consent form. Exclusion Criteria: 1. Known uncontrolled or symptomatic central nervous system metastatic disease. 2. Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade \>1 (National Cancer Institute Common terminology Criteria \[NCI CTCAE\] v.5.0). 3. Inadequate organ or bone marrow function. 4. Pregnant or breast-feeding woman. 5. Known allergies, hypersensitivity, or intolerance to SSGJ-706 The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07171606 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying First-line Advanced NSCLC Patients. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07171606 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07171606 currently recruiting?
Yes, NCT07171606 is actively recruiting participants. Contact the research team at harry_ren@126.com for enrollment information.
Where is the NCT07171606 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT07171606 clinical trial?
NCT07171606 is sponsored by Shenyang Sunshine Pharmaceutical Co., LTD.. The trial plans to enroll 240 participants.